• Home
  • Site Map
  • Contact Us
  • Graphics Version
  • Printer Version

Amarin

Main Navigation

  • ABOUT US
    • COMPANY PROFILE
    • STRATEGY
    • EXECUTIVE MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • THERAPEUTIC FOCUS
    • CARDIOVASCULAR
  • PRODUCTS
    • PIPELINE
    • AMR101 for Reducing Cardiovascular Risk
  • SCIENCE & TECHNOLOGY
    • INTRODUCTION
      • Lipophilic Platform
      • Targeted Lipid Transport Technology Platform
      • Cholinergic Platform
  • PARTNERING
    • PARTNERING
  • INVESTOR RELATIONS
    • OVERVIEW
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
      • AUDIT COMMITTEE
      • REMUNERATION COMMITTEE
      • CODE OF ETHICS
      • MEMORANDUM AND ARTICLES OF ASSOCIATION
    • PRESENTATIONS
    • PRESS RELEASES
    • EVENTS
    • INVESTOR FAQ
    • REQUEST INVESTOR KIT
    • FINANCIAL REPORTS
    • SEC FILINGS
    • EGM 2008
    • ANALYST COVERAGE
    • EMAIL ALERTS
    • REQUEST INFORMATION

INVESTOR RELATIONS

  • OVERVIEW
  • STOCK INFORMATION
  • CORPORATE GOVERNANCE
  • PRESENTATIONS
  • PRESS RELEASES
  • EVENTS
  • INVESTOR FAQ
  • REQUEST INVESTOR KIT
  • FINANCIAL REPORTS
  • SEC FILINGS
  • EGM 2008
  • ANALYST COVERAGE
  • EMAIL ALERTS
  • REQUEST INFORMATION

Mailing List

Mailing List
Unsubscribe »

INVESTOR RELATIONS

EGM 2008

 

Type

Description

File Size

 PDF Amarin Corporation plc 2008 EGM Notice 144KB
 PDF Amarin Corporation plc 2008 EGM Proxy 60KB

 

If you do not have Adobe Acrobat Reader, download it for free.

 

 

Registered in England and Wales No. 2353920 - Registered Office: 110 Cannon Street, London, EC4N 6AR

  • Disclaimer
  • Privacy Policy

© 2010 Amarin

Link opens in new windowWeb Design by Webtrade.ie